BioNet News, Covid-19, Press Releases 21 Mar 2022 Technovalia, Sypharma and BioNet announce the establishment of Genetis, the first Australian Vaccine Development and Manufacturing Hub for mRNA, DNA and recombinant vaccines. Supachai
BioNet News, Covid-19, Press Releases 18 Jan 2022 COVALIA study update: Interim Safety Results from needle-free SARS-CoV2 DNA vaccine phase 1 trial Melbourne 17 January 2022 –Technovalia, an Australian biotech vaccine developer today announced the interim safety results of the ongoing phase… Supachai
Biotech News, Covid-19 24 Sep 2021 Scancell picks PharmaJet’s needle-free injection systems to deliver COVID-19 vaccine candidates Scancell selected Golden, Colorado-based PharmaJet’s devices to administer two SARS-CoV-2 DNA-based vaccine candidates, SCOV1 and SCOV2. The vaccines will be… Supachai
Biotech News, Covid-19 27 Jun 2021 Is a needle-free Covid-19 vaccination possible? The University of Texas Hexapro vaccine candidate, delivered via the UQ-developed and Vaxxas-commercialised high-density microarray patch (HD-MAP), provided protection against… Supachai
BioNet News, Covid-19, Press Releases 24 Sep 2020 COVID-19 vaccine – University of Adelaide researchers are playing a leading role The extended phase 1 human trial will evaluate a COVID-19 gene-based vaccine called COVIGEN, developed by BioNet and Technovalia. The study… Supachai
